Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q4 2022 · 10-K
Revenue$39.00K$39.00K−91.2% vs Q4 2021 Net Income-$16.69M-$16.69MN/M vs Q4 2021 EPS, diluted—
Operating Income-$16,693,000N/M Operating Cash Flowderived-$15,588,500N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$15,588,600N/M Margins · derivedOperating margin-42802.6%−41395.6 pt vs Q4 2021
Net margin-42789.7%−41384.5 pt vs Q4 2021
ended Mar 31, 2022 · filed Jun 23, 2022 · 84 d after period end